A Pilot Feasibility Study Assessing the Combined Effects of Early Behavioral Intervention and Propranolol on Autism Spectrum Disorder (ASD)

被引:1
作者
Hirst, Kathy [1 ]
Zamzow, Rachel M. [2 ]
Stichter, Janine P. [1 ]
Beversdorf, David Q. [1 ,2 ,3 ,4 ,5 ]
机构
[1] Univ Missouri, Thompson Ctr Autism & Neurodev, Columbia, MO 65211 USA
[2] Univ Missouri, Interdisciplinary Neurosci Program, Columbia, MO 65211 USA
[3] Univ Missouri, William & Nancy Thompson Endowed Chair Radiol, Dept Radiol, Columbia, MO 65211 USA
[4] Univ Missouri, William & Nancy Thompson Endowed Chair Radiol, Dept Neurol, Columbia, MO 65211 USA
[5] Univ Missouri, William & Nancy Thompson Endowed Chair Radiol, Dept Psychol Sci, Columbia, MO 65211 USA
来源
CHILDREN-BASEL | 2023年 / 10卷 / 10期
关键词
autism; propranolol; early intervention; clinical trial; BETA-ADRENERGIC MODULATION; COGNITIVE FLEXIBILITY; YOUNG-CHILDREN; NORADRENERGIC MODULATION; PEDIATRIC MIGRAINE; RANDOMIZED-TRIAL; SODIUM VALPROATE; ADOLESCENTS; PREVENTION; MEMANTINE;
D O I
10.3390/children10101639
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Autism spectrum disorder (ASD), a neurodevelopmental disorder typified by differences in social communication as well as restricted and repetitive behaviors, is often responsive to early behavioral intervention. However, there is limited information on whether such intervention can be augmented with pharmacological approaches. We conducted a double-blinded, placebo-controlled feasibility trial to examine the effects of the beta-adrenergic antagonist propranolol combined with early intensive behavioral intervention (EIBI) for children with ASD. Nine participants with ASD, ages three to ten, undergoing EIBI were enrolled and randomized to a 12-week course of propranolol or placebo. Blinded assessments were conducted at baseline, 6 weeks, and 12 weeks. The primary outcome measures focusing on social interaction were the General Social Outcome Measure-2 (GSOM-2) and Social Responsiveness Scale-Second Edition (SRS-2). Five participants completed the 12-week visit. The sample size was insufficient to evaluate the treatment efficacy. However, side effects were infrequent, and participants were largely able to fully participate in the procedures. Conducting a larger clinical trial to investigate propranolol's effects on core ASD features within the context of behavioral therapy will be beneficial, as this will advance and individualize combined therapeutic approaches to ASD intervention. This initial study helps to understand feasibility constraints on performing such a study.
引用
收藏
页数:12
相关论文
共 82 条
[1]   Beta-adrenergic modulation of cognitive flexibility during stress [J].
Alexander, Jessica K. ;
Hillier, Ashleigh ;
Smith, Ryan M. ;
Tivarus, Madalina E. ;
Beversdorf, David Q. .
JOURNAL OF COGNITIVE NEUROSCIENCE, 2007, 19 (03) :468-478
[2]  
AMAN MG, 1985, AM J MENT DEF, V89, P485
[3]  
American Psychiatric Association, 1994, Diagnostic and statistical manual of mental disorders, V4th ed., DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]
[4]   Sodium Valproate versus Propranolol in paediatric migraine prophylaxis [J].
Ashrafi, MR ;
Shabanian, R ;
Zamani, GR ;
Mahfelati, F .
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2005, 9 (05) :333-338
[5]   Association of Genetic and Environmental Factors With Autism in a 5-Country Cohort [J].
Bai, Dan ;
Yip, Benjamin Hon Kei ;
Windham, Gayle C. ;
Sourander, Andre ;
Francis, Richard ;
Yoffe, Rinat ;
Glasson, Emma ;
Mahjani, Behrang ;
Suominen, Auli ;
Leonard, Helen ;
Gissler, Mika ;
Buxbaum, Joseph D. ;
Wong, Kingsley ;
Schendel, Diana ;
Kodesh, Arad ;
Breshnahan, Michaeline ;
Levine, Stephen Z. ;
Parner, Erik T. ;
Hansen, Stefan N. ;
Hultman, Christina ;
Reichenberg, Abraham ;
Sandin, Sven .
JAMA PSYCHIATRY, 2019, 76 (10) :1035-1043
[6]   Sensory Experiences Questionnaire: discriminating sensory features in young children with autism, developmental delays, and typical development [J].
Baranek, Grace T. ;
David, Fabian J. ;
Poe, Michele D. ;
Stone, Wendy L. ;
Watson, Linda R. .
JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY, 2006, 47 (06) :591-601
[7]   Oxytocin and experimental therapeutics in autism spectrum disorders [J].
Bartz, Jennifer A. ;
Hollander, Eric .
ADVANCES IN VASOPRESSIN AND OXYTOCIN: FROM GENES TO BEHAVIOUR TO DISEASE, 2008, 170 :451-462
[8]  
Beversdorf D.Q., 2013, Psychopharmacology
[9]  
Beversdorf David, 2008, Mo Med, V105, P390
[10]   Effect of propranolol on verbal problem solving in autism spectrum disorder [J].
Beversdorf, David Q. ;
Carpenter, Allen L. ;
Miller, Regan F. ;
Cios, Jacquelyne S. ;
Hillier, Ashleigh .
NEUROCASE, 2008, 14 (04) :378-383